Trinefron (goldenrod, rosemary, lovage) capsules №60

Description

Trinefron (goldenrod, rosemary, lovage) capsules №60

Composition

active substances: 1 capsule contains crushed medicinal plant raw materials:

• goldenrod (Centaurii herba) 18 mg;
• rosemary leaves (Rosmarini folium) 18 mg;
• lovage root (Levistici radix) 18 mg.

Excipients: lactose monohydrate; povidone; corn starch; colloidal anhydrous silica; magnesium stearate; capsule shell containing yellow FCF (E 110), titanium dioxide (E 171), gelatin, black ink (in the case of application of the trademark – ST; containing Glaze shellac 45% solution in ethanol, iron oxide black (E 172) , propylene glycol, ammonia solution concentrated).

Dosage form

Capsules.

Basic physical and chemical properties: hard gelatin capsules of orange color. Capsule content is a mixture containing granules and powder from light brown to brown. The presence of agglomerates of particles is allowed. On the capsule it is allowed to apply the trademark of the enterprise – ST.

Pharmacotherapeutic group

Means used in urology.
ATX code G04B X50.

Pharmacological properties

The components of the herbal medicine have a complex activity Trinefron capsules, which is manifested in anti-inflammatory, antioxidant, antispasmodic and analgesic effects. The drug also has antibacterial and diuretic effects, which are due to substances contained in the plant components of the drug.

Indication:

• for complex treatment of inflammatory diseases of the urinary tract;
• prevention of urinary stones, including after their removal.

Contraindication

Hypersensitivity to any component of the preparation or to other plants of the Apiaceae family, such as anise, fennel, and to anethole (ie a component of essential oils containing, for example, anise and fennel).

Peptic ulcer in the acute stage.

Edema due to heart failure or renal impairment and / or physician’s recommendation to limit fluid intake.

Use during pregnancy or breastfeeding

Pregnancy. Observational experience in pregnant women indicates no risk of fetal malformations or fetal / neonatal capsule toxicity. It is known that in experimental studies no signs of reproductive toxicity were obtained. The use of the drug during pregnancy is possible after consultation with a doctor.
Breast-feeding. Due to the lack of data on the drug or its metabolites in breast milk, the risk to infants cannot be ruled out. Therefore, the drug should not be used during breastfeeding.
Ability to influence the speed of reaction when driving a car or working with other mechanisms
The drug does not affect the ability to drive or operate machinery.

Method of application and dosage

Unless otherwise prescribed by a doctor, the drug Trinefron capsules should be taken by adults and children over 12 years of age – 2 capsules 3 times a day (total daily dose – 6 capsules). Capsules should be swallowed without chewing, with enough liquid (eg a glass of water). At the same time with the drug it is necessary to ensure the consumption of sufficient fluids.

The duration of treatment is determined by the doctor individually. If the drug is well tolerated, it can be prescribed for a long time.

Children

The drug is not recommended for use in children under 12 years of age.

Overdose

Cases of drug poisoning due to its overdose are unknown.

Therapy: symptomatic.

Side effects

Often there are disorders of the digestive tract (nausea, vomiting, diarrhea). Allergic reactions may occur in case of hypersensitivity to the components of the drug, including urticaria, itching, redness of the skin.

If any adverse reactions occur, discontinue use and consult a physician.